Searchable abstracts of presentations at key conferences in endocrinology

ea0016p721 | Thyroid | ECE2008

Clinical impact of positron emission tomography/computed tomography in the follow-up of well differentiated thyroid carcinoma with elevated anti-thyroglobuline auto-antibodies

Zerdoud Slimane , Dierickx Lawrence , Benlyazid Adil , Sarini Jerome , Dahimene Samir , Bastie Delphine , Bennet Antoine , Courbon Frederic , Caron Philippe

Aim: Assessment of the clinical impact of a positron emission tomography/computed tomography (PET/CT) with FDG in the management of differentiated thyroid cancer (DTC) in patients with increased or positive thyroglobulin autoantibodies (AbTg).Methodology: Retrospective study involving 15 patients seen in the follow-up with confirmed DTC primarily treated with total thyroidectomy and Iodine 131. Patients presenting with increased AbTg and a negative or no...

ea0009oc6 | Oral Communication 1: Diabetes and metabolism | BES2005

Analysis of post-translational processing and trafficing of agouti-related protein

Pritchard L , Creemers J , Gyte A , Davies N , Le Rouzic P , Lawrence C , Luckman S , Brennand J , White A

Agouti-related protein (AGRP) plays a key role in energy homeostasis with the carboxy-terminal domain acting as an endogenous antagonist of the melanocortin-4 receptor (MC4-R). It has been suggested that the amino-terminal domain of AGRP binds to syndecan-3, allowing it to regulate local concentrations of AGRP at the MC4-R. This model assumes that AGRP is secreted as a full-length peptide. However, AGRP contains several consensus prohormone convertase cleavage sites: Lys52-Lys...

ea0095p133 | Miscellaneous/other 2 | BSPED2023

Patient and public involvement: Techniques used to engage with children and young people about research in congenital adrenal hyperplasia

Tonge Joseph , Bacila Irina , Barker Nicki , Aslam Muniba , Salim Eliza , Walsh James , Phillips Bob , Krone Nils , Lawrence Neil

Background: Incorporating the ideas and views of children and young people (CYP) with endocrine conditions from early stages in the research life cycle will increase the benefit for patients and contribute to high impact research.Methods: We conducted two days of patient and public involvement (PPI) sessions with patients from a tertiary endocrine centre who are living with Congenital Adrenal Hypoplasia (CAH). We explore...

ea0051oc7.7 | Oral Communications 7 | BSPED2017

Role of Degludec in improving diabetes outcomes in young people - An observational study from Young Diabetes Connections (YDC) Network, London

Nambisan Aparna K R , Fredriksen Samantha , Rowland Amy , Morrow Hannah , Castro-Gonzalez Marie , Ajzensztejn Michal , Hulse Tony , Lawrence Joanna , Shamekh Ahmed , Ford-Adams Martha , Chapman Simon

Introduction: YDC is a partnership of four hospital trusts;Kings College Hospital, Princess Royal University Hospital, Lewisham University Hospital and Evelina London Children’s Hospital,caring for a total of 492 children and young people with diabetes. Most young people are on conventional long acting insulin (Levemir and Glargine), but increasingly, poorly controlled patients (HbA1C>100 mmol/mol) with high admission rates are being switched to insulin Degludec due t...

ea0037oc8.5 | Endocrine tumours | ECE2015

Oestrogen receptor α promotes prostate cancer progression through dual actions in both epithelia and stroma

Lawrence Mitchell , Pidsley Ruth , Ellem Stuart , Furic Luc , Nair Shalima , French Hugh , Stratham Aaron , Larsson Ola , Frydenberg Mark , Pedersen John , Buchanan Grant , Taylor Renea , Clark Susan , Risbridger Gail

In human prostate, Oestrogen receptor α (ERα) expression in the epithelium increases with tumour Grade and promotes proliferation involving classical genomic and rapid non-genomic signalling, as well as transcription regulation of non-coding RNA. Similarly, in the tumour stroma there is up-regulation of ERα, corresponding with declining AR, resulting in a higher ratio of ERα:AR with increasing Grade. Additionally, in prostate cancer-associated fibroblasts (...

ea0027oc2.8 | Oral Communications 2 (Quick Fire) | BSPED2011

Novel SOX2 mutation: from clinical phenotype to identification of new molecular mechanisms of SOX2 action and interactions

Alatzoglou Kyriaki S , Andoniadou Cynthia L , Kelberman Daniel , Kim Hyoong-Goo , Pedersen-White Jennifer , Layman Lawrence , Martinez-Barbera Juan Pedro , Dattani Mehul T

Background: SOX2 is an early developmental transcription factor implicated in pituitary development. It consists of a N-terminal domain, a high mobility group (HMG)-DNA binding domain and a carboxyl-terminal domain. Heterozygous SOX2 mutations have been described in patients with a severe ocular phenotype and hypogonadotrophic hypogonadism (HH) with/without associated abnormalities. In vitro SOX2 interacts with β-catenin, a member of the Wnt signalling pathway, and...

ea0094p12 | Adrenal and Cardiovascular | SFEBES2023

Service evaluation suggests variation in clinical care provision in adults with congenital adrenal hyperplasia in the UK and Ireland

Madden Doyle Lauren , Faisal Ahmed Syed , Elford Sue , Elhassan Yasir , James Lynette , Lawrence Neil , Llahana Sofia , Rees Aled , Tomlinson Jeremy , O'Reilly Michael , Krone Nils

Background: The Congenital adrenal Hyperplasia (CAH) Adult Study Executive (CaHASE) identified poor metabolic outcomes and reduced quality of life in CAH. CaHASE2 was recently established to examine the current status of CAH care. We surveyed clinical practice in the UK and Ireland, and awareness and use of the International CAH (I-CAH) Registry.Methods: We undertook an anonymised online survey targeting clinicians provi...

ea0098c25 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

A pilot study of pembrolizumab and peptide receptor radionuclide therapy for patients with metastatic well-differentiated neuroendocrine tumors

Fidelman MD Nicholas , Keenan MD, PhD Bridget P. , Oh MD David Y. , Fong MD Lawrence , Chan BS Kira , Zhang PhD Li , Bergsland MD Emily K. , Hope MD Thomas A.

Background: Expected progression free survival (PFS) for patients with grade 3 well-differentiated neuroendocrine tumors (WD NET) treated with peptide receptor radionuclide therapy (PRRT) is approximately 9 months, and objective response rate (ORR) is 35%. Response rate to single agent immune checkpoint inhibitors (ICI) for patients with G1-3 NET is <15%. Delivery of targeted radiation using PRRT may potentiate the anti-tumor immune response. The purpose of this study is t...

ea0066ds1.1 | Session 1 | BSPED2019

Nutrition, food science and cooking – what role in management of diabetes in children?

Annan Francesca

This presentation will review the role of nutrition in diabetes management, the evolution of advice from RD Lawrence’s Red and Black lines through to the evidence from the current era of the need to consider meal compensation as the basis for insulin dosing with food, the importance of quality of good choices on outcomes, the impact of technology on our understanding of post prandial glucose responses and insulin delivery strategies....

ea0078oc4.7 | Oral Communications 4 | BSPED2021

The use of urinary steroid profiles in monitoring therapy in children with 21-hydroxylase deficiency – results from the CAH-UK cohort study

Bacila Irina , Lawrence Neil , Alvi Sabah , Cheetham Timothy , Crowne Elizabeth , Das Urmi , Dattani Mehul , Davies Justin H , Gevers Evelien , Krone Ruth , Kyriakou Andreas , Patel Leena , Randell Tabitha , Ryan Fiona , S Faisal Ahmed , Keevil Brian , Taylor Norman , Krone Nils

Introduction: Monitoring glucocorticoid (GC) replacement in patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) remains challenging. There are disease-specific patterns in the plasma and urinary steroid profiles in 21OHD, a key role being played by the 11-oxygenatedC19 androgens. Aim: To explore the urinary steroid profile in 21OHD in relation to treatment and plasma steroids. Methods: Partic...